483 related articles for article (PubMed ID: 34804055)
1. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation.
Jarlhelt I; Nielsen SK; Jahn CXH; Hansen CB; Pérez-Alós L; Rosbjerg A; Bayarri-Olmos R; Skjoedt MO; Garred P
Front Immunol; 2021; 12():767981. PubMed ID: 34804055
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.
Adeniji OS; Giron LB; Purwar M; Zilberstein NF; Kulkarni AJ; Shaikh MW; Balk RA; Moy JN; Forsyth CB; Liu Q; Dweep H; Kossenkov A; Weiner DB; Keshavarzian A; Landay A; Abdel-Mohsen M
mBio; 2021 Apr; 12(2):. PubMed ID: 33879594
[TBL] [Abstract][Full Text] [Related]
3. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
[TBL] [Abstract][Full Text] [Related]
4. Clinical and antibody characteristics reveal diverse signatures of severe and non-severe SARS-CoV-2 patients.
Wang H; Yan D; Li Y; Gong Y; Mai Y; Li B; Zhu X; Wan X; Xie L; Jiang H; Zhang M; Sun M; Yao Y; Zhu Y
Infect Dis Poverty; 2022 Feb; 11(1):15. PubMed ID: 35109926
[TBL] [Abstract][Full Text] [Related]
5. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.
Okuya K; Hattori T; Saito T; Takadate Y; Sasaki M; Furuyama W; Marzi A; Ohiro Y; Konno S; Hattori T; Takada A
Microbiol Spectr; 2022 Apr; 10(2):e0155321. PubMed ID: 35319248
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects.
Achiron A; Gurevich M; Falb R; Dreyer-Alster S; Sonis P; Mandel M
Clin Microbiol Infect; 2021 Sep; 27(9):1349.e1-1349.e6. PubMed ID: 33975009
[TBL] [Abstract][Full Text] [Related]
7. Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19.
Kim DM; Kim Y; Seo JW; Lee J; Park U; Ha NY; Koh J; Park H; Lee JW; Ro HJ; Yun NR; Kim DY; Yoon SH; Na YS; Moon DS; Lim SC; Kim CM; Jeon K; Kang JG; Jang NY; Jeong H; Kim J; Cheon S; Sohn KM; Moon JY; Kym S; Han SR; Lee MS; Kim HJ; Park WY; Choi JY; Shin HW; Kim HY; Cho CH; Jeon YK; Kim YS; Cho NH
Cell Rep; 2021 Oct; 37(1):109798. PubMed ID: 34587481
[TBL] [Abstract][Full Text] [Related]
8. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X
Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152
[TBL] [Abstract][Full Text] [Related]
9. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
Front Immunol; 2021; 12():723585. PubMed ID: 34489974
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation.
Lamerton RE; Marcial-Juarez E; Faustini SE; Perez-Toledo M; Goodall M; Jossi SE; Newby ML; Chapple I; Dietrich T; Veenith T; Shields AM; Harper L; Henderson IR; Rayes J; Wraith DC; Watson SP; Crispin M; Drayson MT; Richter AG; Cunningham AF
Front Immunol; 2022; 13():838780. PubMed ID: 35860286
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.
Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V
J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688
[TBL] [Abstract][Full Text] [Related]
12. Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity.
Yates JL; Ehrbar DJ; Hunt DT; Girardin RC; Dupuis AP; Payne AF; Sowizral M; Varney S; Kulas KE; Demarest VL; Howard KM; Carson K; Hales M; Ejemel M; Li Q; Wang Y; Peredo-Wende R; Ramani A; Singh G; Strle K; Mantis NJ; McDonough KA; Lee WT
Cell Rep Med; 2021 Jul; 2(7):100329. PubMed ID: 34151306
[TBL] [Abstract][Full Text] [Related]
13. Complement Activation-Independent Attenuation of SARS-CoV-2 Infection by C1q and C4b-Binding Protein.
Beirag N; Varghese PM; Neto MM; Al Aiyan A; Khan HA; Qablan M; Shamji MH; Sim RB; Temperton N; Kishore U
Viruses; 2023 May; 15(6):. PubMed ID: 37376569
[TBL] [Abstract][Full Text] [Related]
14. A poor and delayed anti-SARS-CoV2 IgG response is associated to severe COVID-19 in children.
Sananez I; Raiden SC; Algieri SC; Uranga M; Grisolía NA; Filippo D; De Carli N; Lalla SD; Cairoli H; Chiolo MJ; Meregalli CN; Cohen E; Mosquera G; Marcó Del Pont M; Giménez LI; Gregorio G; Sarli M; Alcalde AL; Davenport C; Bruera MJ; Simaz N; Pérez MF; Nivela V; Bayle C; Alvarez L; Revetria M; Tuccillo P; Agosta MT; Pérez H; Nova SV; Suárez P; Takata EM; García M; Lattner J; Rolón MJ; Coll P; Salvatori M; Piccardo C; Russo C; Varese A; Seery V; Holgado MP; Polo ML; Ceballos A; Nuñez M; Penedo JMG; Ferrero F; Geffner J; Arruvito L
EBioMedicine; 2021 Oct; 72():103615. PubMed ID: 34649078
[TBL] [Abstract][Full Text] [Related]
15. The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients.
Luo H; Jia T; Chen J; Zeng S; Qiu Z; Wu S; Li X; Lei Y; Wang X; Wu W; Zhang R; Zou X; Feng T; Ding R; Zhang Y; Chen YQ; Sun C; Wang T; Fang S; Shu Y
Front Immunol; 2021; 12():632814. PubMed ID: 33763078
[TBL] [Abstract][Full Text] [Related]
16. Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients.
Moura AD; da Costa HHM; Correa VA; de S Lima AK; Lindoso JAL; De Gaspari E; Hong MA; Cunha-Junior JP; Prudencio CR
Sci Rep; 2021 Sep; 11(1):17642. PubMed ID: 34480056
[TBL] [Abstract][Full Text] [Related]
17. Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients.
Liu C; Yu X; Gao C; Zhang L; Zhai H; Hu Y; Liu E; Wang Q; Gao Y; Wei D; Zhang D; Han Y; Zhang X
J Med Virol; 2021 Apr; 93(4):2227-2233. PubMed ID: 33135795
[TBL] [Abstract][Full Text] [Related]
18. Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients.
Patil HP; Rane PS; Shrivastava S; Palkar S; Lalwani S; Mishra AC; Arankalle VA
Viral Immunol; 2021 Apr; 34(3):201-209. PubMed ID: 33656935
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
